Innovating.works Conecta tu I+D

Showing 1 to 20 of 28 results

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | financed

RESPIRE-EXCEL: Respiratory Precision Medicine PhD Training Network Excellence through Systems Biology Spatial and... ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-MSCA-2023-DN-01 Asthma and COPD are prevalent, chronic respiratory diseases, with high incidence and societal costs. Current treatment is based on a ‘one-si...
2024-07-01 - 2029-02-28 | financed

BonePainIII: Identifying mechanisms and novel treatments of bone pain – closing the gap to the clinic. ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-MSCA-2022-DN-01 Musculoskeletal pain from diseases such as arthritis and cancer in the bone affects the quality of life of millions and is a major societal...
2023-07-14 - 2027-12-31 | financed

GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | financed

Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | financed

ISOBIOTICS: Isotopic Labeling of Biotherapeutics ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-MSCA-2021-DN-01 Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatmen...
2022-07-14 - 2027-01-31 | financed

BiocatCodeExpander: Genetic code expansion for biocatalysis and enzyme engineering doctoral network ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-MSCA-2021-DN-01 The expansion of the genetic code for the incorporation of non-canonical amino acids (NCAA) in proteins provides biotechnologists with an am...
2022-07-06 - 2026-12-31 | financed

ETERNAL: Boosting the reduction of the environmental impact of pharmaceutical products throughout their entir... ASTRAZENECA UK LIMITED participó en un HORIZON EUROPE HORIZON-HLTH-2021-IND-07 ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycl...
2022-05-23 - 2026-08-31 | financed

EndoConnect: EU Training Network in understanding the molecular regulation and the role of endo lysosomal process... ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-ITN-2020 The endo-lysosomal system is essential to acquire lipids and nutrients according to the need of the cell and, subsequently, to maintain meta...
2020-09-03 - 2025-03-31 | financed

PRECODE: PancREatic Cancer OrganoiDs rEsearch Network ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-ITN-2019 The PRECODE Network (PancREatic Cancer OrganoiDs rEsearch) central mission is to establish pancreatic organoid research firmly in the Europe...
2019-08-12 - 2024-03-31 | financed

EUROoC: Interdisciplinary training network for advancing Organ on a chip technology in Europe ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-ITN-2018 EUROoC will create a trans-European network of industrially oriented specialists fully trained in development and application of the emergin...
2018-08-21 - 2023-05-31 | financed

BonePainII: A European Training Network to Combat Bone Pain ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-ITN-2018 In Europe 20 - 30% of adults are affected at any one time by musculoskeletal pain such as arthritic pain, lower back pain, pain from osteopo...
2018-08-20 - 2022-12-31 | financed

QuanTII: Quantitative T cell Immunology and Immunotherapy ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-ITN-2017 Health and disease are regulated, to a large extent, by our immune system. The immune system not only protects the body from infectious dise...
2018-05-18 - 2023-08-31 | financed

BigMedilytics: Big Data for Medical Analytics ASTRAZENECA UK LIMITED participó en un H2020 H2020-ICT-2016-2017 There are three main reasons for an immediate innovation action to apply big data technologies in Healthcare. Firstly, a Healthy nation is a...
2017-11-21 - 2021-09-30 | financed

NoMADS: Nonlocal Methods for Arbitrary Data Sources ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-RISE-2017 In NoMADS we focus on data processing and analysis techniques which can feature potentially very complex, nonlocal, relationships within the...
2017-11-08 - 2023-08-31 | financed

LightDyNAmics: DNA as a training platform for photodynamic processes in soft materials ASTRAZENECA UK LIMITED participó en un H2020 H2020-MSCA-ITN-2017 Light interaction with biomaterials is the driving mechanism of fundamental biological processes, from photosynthesis to DNA photodamage, an...
2017-08-29 - 2022-10-31 | financed

EI3POD: EMBL Interdisciplinary International and Intersectorial Postdocs The EIPOD programme was developed in 2007 with the objective of making use of the excellent scientific environment available at EMBL to supp...
2015-05-13 - 2020-11-30 | financed

F³ FACTORY: Flexible Fast and Future Production Processes ASTRAZENECA UK LIMITED participó en un FP7 The F3 consortium’s vision is that the EU’s chemical industry’s competitive position would be strongly enhanced if it could operate modular...
financed

SYNFLOW: Innovative Synthesis in Continuous Flow Processes for Sustainable Chemical Production ASTRAZENECA UK LIMITED participó en un FP7 The SYNFLOW vision is the paradigm shift from batch-wise large volume processes in pharmaceuticals, fine chemicals and intermediates product...
financed

CASYM: Coordinating Action Systems Medicine Implementation of Systems Medicine across Europe ASTRAZENECA UK LIMITED participó en un FP7 The aim of CASyM is a combined large scale effort to sustainably implement Systems Medicine across Europe. For that purpose CASyM will funct...
financed